

Drug Monograph

Drug/Drug **Aristada™ (aripiprazole lauroxil) suspension for**
 Class: **injection/ Atypical Antipsychotic**
 Prepared for: MO HealthNet
 Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Aristada™ is an extended release intramuscular suspension of aripiprazole lauroxil. It is available in a prefilled syringe in 3 different strengths: 441 mg/ 1.6 mL, 662 mg/ 2.4 mL, and 882 mg/ 3.2 mL of aripiprazole lauroxil respectively. All strengths can be given monthly and the 882 mg/3.2 mL can also be dosed every 6 months.
Manufacturer:	Alkermes, Inc. 852 Winter Street Waltham, MA 02451-1420
Indications:	Aristada™ is indicated for the treatment of schizophrenia.
Costs:	\$665.96 per syringe of 441 mg, \$666.17 per syringe of 662 mg, and \$665.65 per syringe of 882 mg Aristada™. Maximum Allowable Cost
Summary of Findings:	The Division recommends adding this drug to the current atypical antipsychotics clinical edit.
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input checked="" type="checkbox"/> Clinical Edit
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Under Solicitation <input checked="" type="checkbox"/> Appropriate Indications <input type="checkbox"/> No PA Required

Prepared By: Erica Schenewerk Pharm.D. Candidate 2016
 Date: January 25, 2016